Table 4 Comparison of the best response by RECIST between the two mutation groups
CR | PR | SD | PD | ORR | DCR | ||
|---|---|---|---|---|---|---|---|
19 del (n = 127) | Gefitinib | 0 | 24 (27.91) | 58 (67.44) | 4 (4.65) | 24 (27.91) | 82 (95.35) |
Erlotinib | 0 | 10 (47.62) | 8 (38.10) | 3 (14.29) | 10 (47.62) | 18 (85.71) | |
Icotinib | 0 | 2 (11.11) | 16 (88.89) | 0 | 2 (11.11) | 18 (100.00) | |
Others | 0 | 0 | 1 (50.00) | 1 (50.00) | 0 | 1 (50.00) | |
Total | 0 | 36 (28.35) | 83 (65.35) | 8 (6.30) | 36 (28.35) | 119 (93.70) | |
21 L858R (n = 153) | Gefitinib | 0 | 23 (23.47) | 59 (60.20) | 16 (16.33) | 23 (23.47) | 82 (83.67) |
Erlotinib | 0 | 4 (18.18) | 15 (68.18) | 3 (13.64) | 4 (18.18) | 19 (86.36) | |
Icotinib | 0 | 8 (28.57) | 17 (60.71) | 3 (10.71) | 8 (28.57) | 25 (89.29) | |
Others | 0 | 0 | 3 (60.00) | 2 (40.00) | 0 | 3 (60.00) | |
Total | 0 | 35(22.87) | 94 (61.44) | 24 (15.69) | 35 (22.87) | 129 (84.31) |